MAY HEMOGLOBIN BE A MEDIATOR OF INCREASED CARDIOVASCULAR RISK IN NAFLD?
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
CARDIOVASCULAR RISK IN NAFLD?
Peltec Angela1, Ivanova Victoria2, Dumbrava Vlada1 , Popovici Mihail21 Clinic of Gastroenterology and Hepatology, Department of Internal Medicine, University of Medicine and Pharmacy 'NicolaeTestemitanu', Kishinev, Republic of Moldova 2Interventional Cardiology, Institute of Cardiology, Kishinev, Republic of Moldova, *email@example.com
NAFLDis associated with a significantly increased risk of adverse vascular events. Hemoglobin(Hb) concentration could affect the cardiovascular system through oxygen supply and blood viscosity.
To investigate the association of Hb concentration with the 10-years risk of cardiovascular events in patients with NAFLD.
A total of 117 patients (mean age: 49,66 ± 9,4 years, 63/117 - 54% females) who had NAFLD were included in the study.
The 10-years risk of cardiovascular events was calculated according to Framingham equation.
The risk score were categorized using predefined cutoffs as intermediate (≤ 20%) and high (> 20%).
Hemoglobin concentration was divided into age- and sex-dependent quintiles to evaluate the association of Hemoglobin concentration with CVD risk factors and clinical covariates including age, sex, systolic and diastolic BP, LDL and HDL cholesterol, serum triglycerides, diabetes, body mass index (BMI), smoking status, and alcohol consumption.
Elevated hemoglobin level (more than 152 g/L) influence cardiovascular risk profile in patient with NAFLD.
Measurement of hemoglobin level may be useful in predicting cardiovascular risk in patient with NAFLD.
THE INTERNATIONAL LIVER CONGRESS 2013
48th ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
AMSTERSDAM, THE NETHERLANDS, APRIL 24 - 28, 2013